Arca
Skip to content
Tools
Tools

CALCRL: Calcitonin gene-related peptide type 1 receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

G protein-coupled receptor which specificity is determined by its interaction with receptor-activity-modifying proteins (RAMPs).

  • Drugs that act on it: 10
  • Approved: 5
  • In phases 1 to 3: 5
  • Sponsors: 6

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CALCRL, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody
  • Protein or peptide

Approved5

  • Rimegepant
  • Atogepant
  • Erenumab
  • Ubrogepant
  • Zavegepant

Phase 31

  • Telcagepant

Phase 24

  • BI-44370
  • Davalintide
  • MK3207
  • Olcegepant

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule880%
    • Antibody110%
    • Protein or peptide110%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 10 act as: Calcitonin gene-related peptide type 1 receptor antagonist; the rest name their own mechanism.
    RimegepantApprovedPfizerSmall moleculeAntagonist—37—
    AtogepantApprovedAbbVieSmall moleculeAntagonist—16—
    ErenumabApprovedAmgenAntibodyAntagonist—14—
    UbrogepantApprovedAbbVieSmall moleculeAntagonist—6—
    ZavegepantApprovedPfizerSmall moleculeAntagonist—5—
    TelcagepantPhase 3Merck & Co. (MSD)Small moleculeAntagonist—0—
    BI-44370Phase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeAntagonist—0—
    DavalintidePhase 2AstraZeneca PharmaceuticalsProtein or peptideAgonistCalcitonin gene-related peptide type 1 receptor agonist0—
    MK3207Phase 2Merck & Co. (MSD)Small moleculeAntagonist—0—
    OlcegepantPhase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeAntagonist—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 31 in all, from ClinicalTrials.gov.
    A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare ProfessionalsRimegepantNot applicableNot yet recruitingChinese PLA General Hospital2026-11-05
    Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target PopulationsRimegepant—Active, not recruitingPfizer2026-10-30
    Acute Treatment of Vestibular Migraine by RimegepantRimegepantPhase 4RecruitingWensheng Qu2026-10-13
    A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of MigraineZavegepantNot applicableNot yet recruitingAmerican Center for Psychiatry and Neurology2026-10-06
    Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyRimegepantPhase 1RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences2026-09-22
    Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)ErenumabPhase 1Not yet recruitingM.D. Anderson Cancer Center2026-09-21
    Biological Profiles of Neuropeptides, Neurotrophins and miRNA in MigraineRimegepant—Enrolling by invitationNordlandssykehuset HF2026-09-21
    Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineAtogepantPhase 4Not yet recruitingKonrad Peter Weber2026-09-17
    Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell CarcinomaRimegepantPhase 2Not yet recruitingShanghai Zhongshan Hospital2026-09-10
    Rimegepant For Endometriosis PainRimegepantPhase 2Not yet recruitingMayo Clinic2026-08-31
    A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority StudyRimegepantPhase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2026-08-07
    Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster HeadacheZavegepantPhase 2Not yet recruitingThe University of Texas Health Science Center, Houston2026-07-20
    Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United KingdomAtogepant—Not yet recruitingAbbVie2026-07-08
    A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentZavegepantPhase 1RecruitingUniversity of South Florida2026-06-25
    Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Atogepant, ErenumabPhase 4Not yet recruitingStanford University2026-06-17
    Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's DiseaseErenumabEarly phase 1RecruitingXuanwu Hospital, Beijing2026-01-07
    Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine AttacksUbrogepant—RecruitingAbbVie2025-12-30
    Real-world Prospective Study on the Use of Anti-CGRP Drugs in MigraineAtogepant, Erenumab—RecruitingHospital Universitari Vall d'Hebron Research Institute2025-09-08
    i-NEED: NEw migrainE Drugs DatabaseAtogepant, Erenumab—RecruitingIRCCS San Raffaele Roma2025-08-05
    A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineZavegepantPhase 1RecruitingPfizer2025-05-29
    Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyAtogepantPhase 4RecruitingMayo Clinic2025-05-14
    Neurophysiological and Biomolecular Effects of Atogepant in Episodic MigraineAtogepant—RecruitingIRCCS National Neurological Institute "C. Mondino" Foundation2025-03-18
    A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsAtogepantPhase 3RecruitingAbbVie2025-02-05
    Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP AntibodiesErenumab—Active, not recruitingFundación de Investigación Biomédica - Hospital Universitario de La Princesa2024-06-14
    Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineUbrogepantPhase 3Active, not recruitingAbbVie2024-05-16
    Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsZavegepantPhase 4RecruitingMayo Clinic2024-05-07
    Migraine Medication Effects on Urinary SymptomsErenumab, Ubrogepant—Enrolling by invitationThe Cleveland Clinic2024-01-19
    Aimovig Pregnancy Exposure RegistryErenumab—RecruitingAmgen2023-11-29
    Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During PregnancyUbrogepant—RecruitingAbbVie2021-12-15
    Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)UbrogepantPhase 3Enrolling by invitationAbbVie2021-11-19
    Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)UbrogepantPhase 3RecruitingAbbVie2021-11-18

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Lymphatic malformation 8
    0.41
    Hypertensive disorder
    0.40
    Non-immune hydrops fetalis
    0.37
    Hyperprolactinemia
    0.37
    Tachycardia
    0.35
    Coronary artery disorder
    0.30
    Obesity disorder
    0.30
    Cancer
    0.27
    Non-alcoholic fatty liver
    0.26

    Genes and Related Targets

    Complexes and families that share a gene with this target
    Genes
    CALCRL

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3798, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q16602, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.